MX2017012470A - Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico. - Google Patents

Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.

Info

Publication number
MX2017012470A
MX2017012470A MX2017012470A MX2017012470A MX2017012470A MX 2017012470 A MX2017012470 A MX 2017012470A MX 2017012470 A MX2017012470 A MX 2017012470A MX 2017012470 A MX2017012470 A MX 2017012470A MX 2017012470 A MX2017012470 A MX 2017012470A
Authority
MX
Mexico
Prior art keywords
treatment
agonists
methods
retinoic acid
acid receptor
Prior art date
Application number
MX2017012470A
Other languages
English (en)
Inventor
Wei Chen Mei
Collins Cindy
Lucas EATON Matthew
G Guenther Matthew
KE Nan
LOPEZ Jeremy
R Mckeown Michael
A Orlando David
Original Assignee
Syros Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syros Pharmaceuticals Inc filed Critical Syros Pharmaceuticals Inc
Publication of MX2017012470A publication Critical patent/MX2017012470A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona métodos que definen poblaciones celulares que son sensibles a agonistas RARA e identifican subgrupos de pacientes que se beneficiarían del tratamiento con agonistas RARA. La invención también proporciona composiciones farmacéuticas empacadas que comprenden un agonista RARA e instrucciones para determinar si tal agonista es apropiado para uso en el tratamiento.
MX2017012470A 2015-03-31 2016-03-31 Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico. MX2017012470A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140999P 2015-03-31 2015-03-31
US201562268203P 2015-12-16 2015-12-16
PCT/US2016/025256 WO2016161107A1 (en) 2015-03-31 2016-03-31 METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-α AGONISTS

Publications (1)

Publication Number Publication Date
MX2017012470A true MX2017012470A (es) 2018-03-23

Family

ID=57006493

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012470A MX2017012470A (es) 2015-03-31 2016-03-31 Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
MX2022005020A MX2022005020A (es) 2015-03-31 2017-09-28 Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005020A MX2022005020A (es) 2015-03-31 2017-09-28 Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.

Country Status (14)

Country Link
US (5) US9845508B2 (es)
EP (2) EP3967305A1 (es)
JP (3) JP6952604B2 (es)
KR (1) KR20170132248A (es)
CN (2) CN107613969B (es)
AU (2) AU2016243702B2 (es)
BR (3) BR122023024813A2 (es)
CA (1) CA2981518A1 (es)
ES (1) ES2901792T3 (es)
HU (1) HUE057325T2 (es)
IL (3) IL309066A (es)
MX (2) MX2017012470A (es)
PL (1) PL3277272T3 (es)
WO (1) WO2016161107A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145295A1 (en) 2013-03-15 2014-09-18 Avisenna Cosmetics, Llc Topical compositions for reducing aging effects
EP3967305A1 (en) 2015-03-31 2022-03-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
MX2018012250A (es) * 2016-04-08 2019-06-24 Syros Pharmaceuticals Inc Agonistas de los receptores de acido retinoico alfa (rara) para el tratamiento de leucemia mieloide aguda (aml) y sindrome mielodisplasico (mds).
WO2018067946A1 (en) * 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
WO2018136961A1 (en) * 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY
JP2019043865A (ja) * 2017-08-31 2019-03-22 ひまわり製薬株式会社 ざ瘡様疾患を治療又は予防するための皮膚外用組成物
WO2020069187A1 (en) * 2018-09-28 2020-04-02 The Children's Medical Center Corporation Combination therapy for acute myeloid leukemia
US20230285339A1 (en) * 2020-08-06 2023-09-14 Syros Pharmaceuticals, Inc. Therapies for treating aml and uses of rara agonists, hypomethylating agents, and bcl-2 inhibitors
CN112390731B (zh) * 2020-11-16 2022-11-25 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3580134D1 (de) 1984-07-07 1990-11-22 Shudo Koichi Prof Dr Chem Benzoesaeurederivate.
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
JP2752630B2 (ja) 1988-03-29 1998-05-18 大鵬薬品工業株式会社 新規安息香酸誘導体及びその製造方法
WO1992016660A1 (en) 1991-03-22 1992-10-01 Sloan-Kettering Institute For Cancer Research Methods for detection and treatment of cancer
US5759785A (en) 1992-05-14 1998-06-02 Baylor College Of Medicine Method of identifying hormone antagonists and agonists
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
FR2739777B1 (fr) 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
NZ331466A (en) 1996-03-18 2000-06-23 Eisai Co Ltd Fused-ring carboxylic acid derivatives
US6329179B1 (en) 1996-03-26 2001-12-11 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999020309A1 (fr) 1997-10-22 1999-04-29 Eisai Co., Ltd. Agonistes de l'acide retinoique, agents preventifs et therapeutiques des nephrites
CA2359816C (en) 1999-01-06 2010-08-03 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
TWI281911B (en) 2000-04-04 2007-06-01 Allergan Inc Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
AU2002328226A1 (en) * 2001-09-17 2003-04-01 Angiogene Inc. Modulation of retinoic acid receptor gene expression and therapeutic uses thereof
JP5113038B2 (ja) 2006-03-23 2013-01-09 テムリック株式会社 癌治療用キットおよび癌治療用医薬組成物
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
MX2009009997A (es) 2007-03-30 2009-12-08 Tmrc Co Ltd Preparacion de la capsula de tamibarotene.
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20100099084A1 (en) 2008-10-17 2010-04-22 Maher Albitar Detection of npm1 nucleic acid in acellular body fluids
US20130165520A1 (en) * 2010-02-11 2013-06-27 University De Montreal Hybrid Molecule Having Mixed Retinoic Acid Receptor Agonism and Histone Deacetylase Inhibitory Properties
ES2691493T3 (es) 2012-06-07 2018-11-27 Childrens Hospital Los Angeles Métodos para tratar la neutropenia usando agonistas retinoides
US20140287932A1 (en) 2012-10-25 2014-09-25 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
US20140296218A1 (en) 2012-10-25 2014-10-02 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
WO2014150300A2 (en) 2013-03-15 2014-09-25 Abbott Molecular Inc. Method for amplification and assay of rna fusion gene variants, method of distinguishing same and related primers, probes, and kits
US20160235842A1 (en) 2013-07-15 2016-08-18 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists
MX2016007239A (es) 2013-12-06 2017-01-05 Celgene Corp Metodos para determinar la eficacia del farmaco para el tratamiento de linfoma difuso de celulas b grandes, mieloma multiple, y canceres mieloides.
US11077139B2 (en) 2013-12-30 2021-08-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
US20160317654A1 (en) 2015-03-09 2016-11-03 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
EP3967305A1 (en) 2015-03-31 2022-03-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
DK3380086T3 (da) 2015-11-25 2021-11-22 Io Therapeutics Inc Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
US9868994B2 (en) * 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
MX2018012250A (es) 2016-04-08 2019-06-24 Syros Pharmaceuticals Inc Agonistas de los receptores de acido retinoico alfa (rara) para el tratamiento de leucemia mieloide aguda (aml) y sindrome mielodisplasico (mds).
WO2018067946A1 (en) 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
WO2018136961A1 (en) 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY

Also Published As

Publication number Publication date
IL254697A0 (en) 2017-11-30
CN107613969B (zh) 2022-07-22
BR122023024813A2 (pt) 2024-02-20
WO2016161107A1 (en) 2016-10-06
ES2901792T3 (es) 2022-03-23
US10167518B2 (en) 2019-01-01
CA2981518A1 (en) 2016-10-06
CN116059365A (zh) 2023-05-05
IL294449B2 (en) 2024-05-01
AU2022200059A1 (en) 2022-02-03
BR112017020745A2 (pt) 2018-07-17
IL294449A (en) 2022-09-01
EP3277272A4 (en) 2018-09-26
US20180187271A1 (en) 2018-07-05
JP2018514517A (ja) 2018-06-07
HUE057325T2 (hu) 2022-04-28
EP3967305A1 (en) 2022-03-16
US20180087115A1 (en) 2018-03-29
JP2022185101A (ja) 2022-12-13
US20200392583A1 (en) 2020-12-17
AU2016243702A1 (en) 2017-10-26
US20160355888A1 (en) 2016-12-08
PL3277272T3 (pl) 2022-01-24
AU2016243702B2 (en) 2021-10-07
US9845508B2 (en) 2017-12-19
IL254697B (en) 2022-08-01
RU2017134582A3 (es) 2019-12-13
EP3277272A1 (en) 2018-02-07
IL309066A (en) 2024-02-01
US10697025B2 (en) 2020-06-30
CN107613969A (zh) 2018-01-19
IL294449B1 (en) 2024-01-01
AU2022200059B2 (en) 2024-05-23
MX2022005020A (es) 2022-05-16
US11447831B2 (en) 2022-09-20
BR122023024814A2 (pt) 2024-02-20
KR20170132248A (ko) 2017-12-01
US20230042181A1 (en) 2023-02-09
EP3277272B1 (en) 2021-08-04
JP2020203911A (ja) 2020-12-24
JP6952604B2 (ja) 2021-10-20
RU2017134582A (ru) 2019-04-04

Similar Documents

Publication Publication Date Title
MX2022005020A (es) Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
MX2019004931A (es) Comparacion disimetrica de valores de humedad subepidermica.
SA517390218B1 (ar) جهاز وطرق لتحديد النسيج التالف باستخدام قياسات الرطوبة تحت الجلد
HRP20181841T1 (hr) Sukristali (s)-n-metil-8-(1-((2′-metil-[4,5′-bipirimidin]-6-il)amino)propan-2-il)kinolin-4-karboksamida i njegovih deuteriranih derivata kao inhibitora dna-pk
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
EP3248544A4 (en) Device for measuring concentration of substance in blood, and method for measuring concentration of substance in blood
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
ZA201700924B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
GB201411465D0 (en) Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
MX2016010998A (es) Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
IL257784A (en) Methods and compositions for reducing fat
HK1258665A1 (zh) 色氨酸雙加氧酶(ido1和tdo)抑制劑及其在治療中的用途
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
TN2014000498A1 (en) Pharmaceutical formulation
WO2018067946A8 (en) METHODS OF TREATING PATIENTS USING RETINOIC ACID ALPHA RECEPTOR AGONIST AND ANTI-CD38 ANTIBODY
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
MA40590A (fr) Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase
MX2018012250A (es) Agonistas de los receptores de acido retinoico alfa (rara) para el tratamiento de leucemia mieloide aguda (aml) y sindrome mielodisplasico (mds).
EA201692432A1 (ru) Способ и устройство для определения времени распадаемости пленочной лекарственной формы
NZ719745A (en) Soluble fc gamma receptor for treatment of autoimmune bullous diseases
FR3030280B1 (fr) Composition filmogene et son utilisation pour le traitement des affections bucco-linguales
GB201721222D0 (en) Detection of notch mutations as an aid in the selection of eligible patients for treatment with syntana -4 and other notch inhibitors
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы